International Journal of Bioinformatics and Biomedical Engineering
Articles Information
International Journal of Bioinformatics and Biomedical Engineering, Vol.5, No.1, Dec. 2019, Pub. Date: Oct. 23, 2019
Cancer Immunotherapy by Harnessing Innate Immunity - A Brief History, Mechanism, and Future Applications of the Therapy
Pages: 1-9 Views: 33 Downloads: 18
Authors
[01] Daniel Koenemann, Department of Biology, Howard University, Washington DC, USA.
[02] Mohammed Asiri, Department of Microbiology, Howard University, Washington DC, USA.
[03] Hemayet Ullah, Department of Biology, Howard University, Washington DC, USA.
Abstract
Cancer- 'The Emperor of all Maladies'- a moniker coined by the acclaimed author Siddhartha Mukherjee, continues to be the one of the devastating diseases. Despite spending billions of dollars of research funds, researchers are still at a bay in the war on the cancer diseases. However, recent therapeutic development of harnessing one's own immune system power to fight cancer is showing a slim advantage in favor of the researchers. In this process, the body's immune system is 'trained' to not only recognize and attack specific cancer cells, but also boost immune cells to help them eliminate cancer. Success stories of the immunotherapy have started to trickle down and a greater understanding of the mechanism, challenges, and application will allow new and existing researchers to develop the technology further. With this aim in focus, this review paper discusses the history, the mechanism, applications and future potential of this scintillating technology to fight cancer. A review of the potential applications and the regulatory environment for this technology will help reader develop a better understanding of this novel and unique approach to fight cancer which past decades have only produced treatments that could not lengthen survival rates significantly.
Keywords
Immunity, Immunotherapy, Cancer, Antibody, T-cells, Tregs
References
[01] Passalacqua, G. and G. W. Canonica. 2016. Allergen immunotherapy. Immunology & Allergy Clinics 36 (1): 1-12.
[02] Hewitt, H. B. 1979. A critical examination of the foundations of immunotherapy for cancer. Clinical Radiology 30: 361-369.
[03] Rosenberg, S. A. 1999. A new era of cancer immunotherapy: Converting theory to performance. CA: A Cancer Journal for Clinicians 49 (2): 70-73.
[04] Parish, C. R. 2003. Cancer immunotherapy: The past, the present and the future. Immunology & Cell Biology 81 (2): 106-113.
[05] Decker, W. K., R. F. da Silva, M. H. Sanabria, L. S. Angelo, F. Guimarães, B. M. Burt, F. Kheradmand, S. Paust. 2017. Cancer immunotherapy: Historical perspective of a clinical revolution and emerging preclinical animal models. Frontiers in Immunology 8: 1-13.
[06] Sadava, D., D. M. Hillis, H. C. Heller, M. R. Berenbaum. Life: The Science of Biology, Ninth Edition. Sunderland, MA: Sinauer Associates, 2011.
[07] Order, S. E. 1976. The history and progress of serologic immunotherapy and radiodiagnosis. Radiology 118 (1): doi: 10. 1148/118. 1. 219.
[08] Gubin, M. M. and R. D. Schreiber. 2015. The odds of immunotherapy success: Mutation load correlates with the response of melanomas to immunotherapy. Science 350 (6257): 158-159.
[09] Curiel, T. J. 2007. Tregs and rethinking cancer immunotherapy. The Journal of Clinical Investigation 117 (5): 1167-1174.
[10] Mellman, I., G. Coukos, and G. Dranoff. 2011. Cancer immunotherapy comes of age. Nature 480 (22): 480-489.
[11] Herr, H. W. and A. Morales. 2008. History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success Story. The Journal of Urology 179 (1): 53-56.
[12] Osband, M. E. and S. Ross. 1990. Problems in the investigational study and clinical use of cancer immunotherapy. Immunology Today 1 (6): 193-195.
[13] Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer 12: 252-264.
[14] Frankel, T., M. P. Lanfranca, W. Zou. 2017. The role of tumor microenvironment in cancer immunotherapy. Advances in Experimental Medicine and Biology 1036: 51-64.
[15] Monteiro, J. 2015. Cancer immunotherapy scores again. Cell 160: 7-9.
[16] Maude, S. L., T. W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. R. Verneris, H. E. Stefanski, G. D. Myers, M. Qayed, B. De Moerloose, H. Hiramatsu, K. Schlis, K. L. Davis, P. L. Martin, E. R. Nemecek, G. A. Yanik, C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krueger, C. H. June, B. L. Levine, P. Wood, T. Taran, M. Leung, K. T. Mueller, Y. Zhang, K. Sen, D. Lebwohl, M. A. Pulsipher, and S. A. Grupp. 2018. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. The New England Journal of Medicine 378 (5): 439-448.
[17] Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews Cancer 8: 299-308.
[18] Fox, B. A., D. J. Schendel, L. H. Butterfield, S. Aamdal, J. P. Allison, P. A. Ascierto, M. B. Atkins, J. Bartunkova, L. Bergmann, N. Berinstein, C. C. Bonorino, E. Borden, J. L. Bramson, C. M. Britten, X. Cao, W. E. Carson, A. E. Chang, D. Characiejus, A. R. Choudhury, G. Coukos, T. de Gruijl, R. O. Dillman, M. L. Disis, H. Dolstra, G. Dranoff, L. G. Durrant, J. H. Finke, T. F. Gajewski, J. Galon, J. A. Gollob, C. Gouttefangeas, F. Grizzi, M. Guida, L. Håkansson, K. Hege, R. B. Herberman, F. S. Hodi, A. Hoos, C. Huber, P. Hwu, K. Imai, E. M. Jaffee, S. Janetzki, C. H. June, P. Kalinski, H. L. Kaufman, K. Kawakami, Y. Kawakami, U. Keilholtz, S. N. Khleif, R. Kiessling, B. Kotlan, G. Kroemer, R. Lapointe, H. I. Levitsky, M. T. Lotze, C. Maccalli, M. Maio, F. M. Marincola, J. -P. Marschner, M. J. Mastrangelo, G. Masucci, I. Melero, C. Melief, W. J. Murphy, B. Nelson, A. Nicolini, M. I Nishimura, K. Odunsi, P. S. Ohashi, J. O'Donnell-Tormey, L. J. Old, C. Ottensmeier, M. Papamichail, G. Parmiani, G. Pawelec, E. Proietti, S. Qin, R. Rees, A. Ribas, R. Ridolfi, G. Ritter, L. Rivoltini, P. J. Romero, M. L. Salem, R. J. Scheper, B. Seliger, P. Sharma, H. Shiku, H. Singh-Jasuja, W. Song, P. T. Straten, H. Tahara, Z. Tian, S. H. van Der Burg, P. von Hoegen, E. Wang, M. J. P. Welters, J. M. Wigginton, H. Winter, T. Withington, J. D. Wolchok, W. Xiao, L. Zitvogel, and H. Zwierzina. 2011. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine 9: 214-227.
[19] Couzin-Frankel, J. "Cancer Immunotherapy,” Science Magazine, December 2013, 1432-1433.
[20] Owen, J. A.; Punt, J., Stranford, S. A.; Jones, P P.; and Kuby, J (2013), W. H. Freeman, New York.
[21] Maldarelli, C. "The FDA just approved a game-changing cancer treatment,” Popular Science, August 2017, Online .
[22] Mahoney, K. M., G. J. Freeman, D. F. McDermott. 2015. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics 37 (4): 764-782.
[23] Zhang, L., R. A. Morgan, J. D. Beane, Z. Zheng, M. E. Dudley, S. H. Kassim, A. V. Nahvi, L. T. Ngo, R. M. Sherry, G. Q. Phan, M. S. Hughes, U. S. Kammula, S. A. Feldman, M. A. Toomey, S. P. Kerkar, N. P. Restifo, J. C. Yang, and S. A. Rosenberg. 2015. Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research doi: 10. 1158/1078-0432. CCR-14-2085
[24] Fan, Y. and J. J. Moon. 2015. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines 3: 662-685.
[25] Patrick P. Ng, Ming Jia, Kedar G. Patel, Joshua D. Brody, James R. Swartz, Shoshana Levy, Ronald Levy (2012) Cell-free idiotype vaccine targeted to B cells Proceedings of the National Academy of Sciences Sep 2012, 109 (36) 14526-14531; DOI: 10.1073/pnas.1211018109
[26] Vatsan, R. S., P. F. Bross, K. Lie, M. Theoret, A. R. De Claro, J. Lu, W. Helms, B. Niland, S. R. Husain, and R. K. Puri. 2013. Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation. Journal for Immunotherapy for Cancer 1: 5. doi: 10.1186/2051-1426-1-5.
[27] Lesterhuis, W. J., J. B. A. G. Haanen, and C. J. A. Punt. 2011. Cancer immunotherapy-revisited. Nature Reviews 10: 591-600.
[28] Weber, J. S. and J. J. Mulé. 2015. Cancer immunotherapy meets biomaterials. Nature Biotechnology 33 (1): 44-45.
600 ATLANTIC AVE, BOSTON,
MA 02210, USA
+001-6179630233
AIS is an academia-oriented and non-commercial institute aiming at providing users with a way to quickly and easily get the academic and scientific information.
Copyright © 2014 - American Institute of Science except certain content provided by third parties.